dm+d

350469004

Articles

What factors should be considered when using LMWH to treat venous thromboembolism in patients with high body weight?

14 September 2020Treatment of venous thromboembolism (VTE) in patients with high body weight constitutes a challenge in clinical practice. Adjustments in the dose calculation may be necessary…

Low molecular weight heparins - should treatment doses be used in patients with renal impairment?

25 March 2020Randomised controlled trials evaluating LMWH efficacy and safety have generally excluded patients with severe renal impairment (RI). In contrast to UFH, LMWHs are primarily cleared…

Low molecular weight heparins - should prophylactic doses be used in patients with renal impairment?

23 October 2019This updated Medicines Q & A reviews the evidence available and considers when prophylactic doses of low molecular weight heparins can be used in patients…

What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

4 September 2018This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism
Search Articles

Lactation Safety Information

Yes
-
No published evidence of safety
Low levels anticipated in milk due to the drug’s properties and not absorbed from the infant’s GI tract
Used in infants > 1 month
20 October 2016